Recent Updates
Recently added Catalysts
CGON Positive Sentiment

SUO 2025 – FIRST RESULTS CORE-008 COHORT A PODIUM

Friday, December 5, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CG Oncology has announced positive initial results from the CORE-008 Cohort CX Phase 2 trial. This trial evaluates an intravesical combination therapy aimed at high-risk patients who are either BCG-exposed or BCG-unresponsive. The findings suggest potential advancements in treatment options for these patients.
Price reaction · baseline $44.73 (2025-12-04 close) · hit pre-market · 3 other CGON headline(s) in the window, move may be shared
day 0 close · peak
-3.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive first results reported from CORE-008 Cohort CX trial.
  • Evaluation of intravesical combination therapy shows promise.
  • Targeting high-risk BCG-exposed and unresponsive patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

by admin | Dec 5, 2025 | congress-hub-posters | 0 comments

Recent Posts

• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation

Recent Comments

Frequently Asked Questions

What are the CORE-008 trial results?

The CORE-008 trial reported positive initial results for an intravesical combination therapy.

Who are the patients targeted in the CORE-008 trial?

The trial focuses on high-risk patients who are BCG-exposed or BCG-unresponsive.

What type of therapy is being evaluated in CORE-008?

The trial evaluates an intravesical combination therapy for bladder cancer.

When were the results from CORE-008 presented?

The results were announced on December 5, 2025.

ShareAdd on Google
Tags: CGON Viatris Investor Conferences Healthcare CG Oncology CORE-008 Phase 2 trial intravesical therapy bladder cancer
Last updated: Dec 5, 2025

Biotech snapshot

Cash runway
$1028M liquidity · $15M/mo burn
~66 mo
Minimal dilution risk
Lead asset
CG0070Phase 2
Non Muscle Invasive Bladder Cancer →

Catalyst track record

+139%
best trade around CGON's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for CGON.

See every catalyst's timing & PoA →